期刊
JOURNAL OF CONTROLLED RELEASE
卷 335, 期 -, 页码 527-540出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2021.05.035
关键词
Age-related macular degeneration (AMD); Systemic therapies; PAMAM dendrimers; Microglia/macrophages; Triamcinolone acetonide; Choroidal neovascularization; Retinal inflammation
资金
- National Eye Institute [NEI-R01EY025304, NEI-RO1EY016151, EY01765]
- Research to Prevent Blindness
- Altsheler Durell foundation
The study demonstrates a potential systemic therapy approach for selectively targeting and inhibiting the progression of AMD, showing promising efficacy in animal models and human postmortem studies.
Inflammation and neovascularization are key pathological events in human age-related macular degeneration (AMD). Activated microglia/macrophages (mi/ma) and retinal pigmented epithelium (RPE) play an active role in every stage of disease progression. Systemic therapies that can target these cells and address both inflammation and neovascularization will broaden the impact of existing therapies and potentially open new avenues for early AMD where there are no viable therapies. Utilizing a clinically relevant rat model of AMD that mirrors many aspects that of human AMD pathological events, we show that systemic hydroxyl-terminated polyamidoamine dendrimer-triamcinolone acetonide conjugate (D-TA) is selectively taken up by the injured mi/ma and RPE (without the need for targeting ligands). D-TA suppresses choroidal neovascularization significantly (by >80%, >50-fold better than free drug), attenuates inflammation in the choroid and retina, by limiting macrophage infiltration in the pathological area, significantly suppressing pro-inflammatory cytokines and pro-angiogenic factors, with minimal side effects to healthy ocular tissue and other organs. In ex vivo studies on human postmortem diabetic eyes, the dendrimer is also taken up into choroidal macrophages. These results suggest that the systemic hydroxyl dendrimer-drugs can offer new avenues for therapies in treating early/dry AMD and late/neovascular AMD alone, or in combination with current anti-VEGF therapies. This hydroxyl dendrimer platform but conjugated to a different drug is undergoing clinical trials for severe COVID-19, potentially paving the way for faster clinical translation of similar compounds for ocular and retinal disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据